Study guide

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN

Key Takeaways Explain This Topic AI

The 2025 AHA/ACC High Blood Pressure Guideline, published August 14, 2025, supersedes the 2017 guideline but keeps the same four categories: Normal (<120/<80), Elevated (120-129/<80), Stage 1 (130-139/80-89), and Stage 2 (>=140/>=90 mmHg), with a universal treatment target of <130/80 mmHg.

The PREVENT equations replace the Pooled Cohort Equations; a 10-year PREVENT cardiovascular risk of at least 7.5 percent triggers antihypertensive drug therapy in stage 1 hypertension, and a lower-risk stage 1 patient still starts medication if blood pressure remains at or above 130/80 mmHg after 3 to 6 months of lifestyle therapy.

First-line antihypertensive classes remain thiazide diuretics (chlorthalidone preferred), ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers; initial dual combination therapy is recommended for Stage 2 hypertension when blood pressure is more than 20/10 mmHg above target.

In Black adults without chronic kidney disease or albuminuria, initial monotherapy should be a thiazide-type diuretic or a calcium channel blocker rather than an ACE inhibitor or ARB, based on ALLHAT stroke and blood pressure outcomes.

Resistant hypertension is blood pressure at or above 130/80 mmHg on three maximally tolerated agents of different classes including a diuretic, or controlled blood pressure requiring four or more agents; spironolactone is the preferred fourth agent and the 2025 guideline screens every resistant patient for primary aldosteronism regardless of serum potassium.

Last updated: August 2026

Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN

Hypertension (HTN) is the single largest modifiable contributor to cardiovascular morbidity and all-cause mortality in adult and geriatric populations across the United States. Chronic vascular endothelial shear stress, systemic inflammation, and neurohormonal dysregulation from elevated arterial pressure accelerate atherosclerosis, left ventricular hypertrophy (LVH), congestive heart failure, cerebrovascular accidents (CVA), chronic kidney disease (CKD), and vascular dementia.

For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , board mastery requires precise familiarity with diagnostic classification thresholds, standardized blood pressure measurement protocols, cardiovascular risk-stratified pharmacotherapy initiation, demographic-specific drug selection, and systematic evaluation of secondary and resistant hypertension.

The governing document is now the 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults , published 14 August 2025, which supersedes the 2017 ACC/AHA guideline . AANP is a partner society on that writing committee, and its changes are directly examinable.

Important

What the 2025 guideline changed (and what it did not):

Unchanged: the four blood pressure categories and their numeric cut points, and the universal <130/80 mmHg treatment target.

Changed: the PREVENT risk equations replace the Pooled Cohort Equations, and a 10-year PREVENT CVD risk of >=7.5% is the threshold for starting drug therapy in stage 1 hypertension.

Changed: primary aldosteronism screening is recommended in all resistant hypertension regardless of serum potassium - hypokalemia is no longer a prerequisite.

Changed: the term "hypertensive urgency" is retired ; markedly elevated blood pressure without acute target-organ damage is now called "severe hypertension."

New: potassium-based salt substitutes carry a Class 2a, Level A recommendation.

Upgraded: ACE inhibitors and ARBs are Class 1 in both chronic kidney disease and diabetes, and a systolic target <130 mmHg is now recommended (not merely "reasonable") to reduce cognitive decline and dementia.

New: ACOG-aligned pregnancy recommendations - treat chronic hypertension to <140/90 mmHg, prefer labetalol or extended-release nifedipine, give low-dose aspirin for pre-eclampsia prophylaxis, and avoid ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and nitroprusside.

1. Diagnostic Classification & Blood Pressure Thresholds (2025 ACC/AHA)

The 2017 American College of Cardiology / American Heart Association (ACC/AHA) guideline restructured hypertension classification by lowering diagnostic thresholds, and the 2025 guideline deliberately retained those same four categories and cut points - so the table below is current. What changed in 2025 is not how blood pressure is labeled but how cardiovascular risk is calculated and when drug therapy begins . +-----------------------------------------------------------------------------+

  • | 2025 ACC/AHA BLOOD PRESSURE CATEGORIES (UNCHANGED) |
  • | |
  • | CATEGORY SYSTOLIC BP (mmHg) DIASTOLIC BP (mmHg) |
  • | ----------------------------------------------------------------------- |
  • | NORMAL < 120 AND < 80 |
  • | ELEVATED 120 - 129 AND < 80 |
  • | STAGE 1 HTN 130 - 139 OR 80 - 89 |
  • | STAGE 2 HTN >= 140 OR >= 90 |
  • | SEVERE HYPERTENSION > 180 AND/OR > 120 |
  • +-----------------------------------------------------------------------------+

Clinical Classification Rules:

Classification Logic: When systolic and diastolic pressures fall into different categories, the patient is assigned to the higher (more severe) category (e.g., 128/86 mmHg is classified as Stage 1 HTN).

Diagnosis Confirmation Requirement: Diagnosis of hypertension requires an average of ≥2 accurate blood pressure measurements obtained on ≥2 separate clinical encounters , or confirmation via Out-of-Office Ambulatory Blood Pressure Monitoring (ABPM) / Home Blood Pressure Monitoring (HBPM).

Universal Treatment Goal: For non-institutionalized ambulatory adults (including geriatric patients ≥65 years, patients with diabetes mellitus, and patients with CKD), the standard clinical blood pressure target is < 130/80 mmHg .

2. Standardized Blood Pressure Measurement & Out-of-Office Protocols

Inaccurate measurement technique is the most common cause of spurious hypertension diagnosis and inappropriate pharmacotherapy titration. +-----------------------------------------------------------------------------+

  • | STANDARDIZED CLINICAL BP MEASUREMENT PROTOCOL |
  • | |
  • | [PREPARATION] ---> 5 minutes seated rest in quiet room |
  • | No caffeine, exercise, or smoking within 30 min |
  • | Empty bladder prior to measurement |
  • | | |
  • | v |
  • | [POSITIONING] ---> Seated with back supported, legs uncrossed |
  • | Feet resting flat on the floor |
  • | Bare arm supported at mid-sternal / heart level |
  • | | |
  • | v |
  • | [CUFF SIZING] ---> Bladder length encircles 80-100% of arm circumference|
  • | Bladder width covers >= 40% of arm circumference |
  • | | |
  • | v |
  • | [TECHNIQUE] ---> 2 readings taken 1-2 min apart; record average |
  • | Initial visit: check both arms; use higher arm |
  • +-----------------------------------------------------------------------------+

Common Artifacts & Diagnostic Nuances:

Cuff Too Small / Narrow: Overestimates systolic and diastolic BP (falsely elevated by 5–15 mmHg).

Cuff Too Large / Wide: Underestimates systolic and diastolic BP (falsely low).

Unsupported Arm / Arm Below Heart Level: Hydrostatic column increases measured pressure by up to 10 mmHg.

White Coat Hypertension: Office BP ≥130/80 mmHg but daytime ABPM/HBPM <130/80 mmHg. Confirm with daytime ABPM/HBPM before initiating pharmacotherapy.

Masked Hypertension: Office BP <130/80 mmHg but ABPM/HBPM ≥130/80 mmHg (high cardiovascular risk, associated with target-organ damage like LVH or microalbuminuria).

Orthostatic (Postural) Hypotension Assessment: Check supine/seated BP, then standing BP at 1 and 3 minutes. Defined as a drop in SBP ≥20 mmHg or DBP ≥10 mmHg. Mandatory assessment in older adults and diabetic patients before intensifying antihypertensives.

3. Cardiovascular Risk Stratification & Treatment Initiation Algorithm

Pharmacological treatment decisions depend on baseline blood pressure staging combined with the patient's calculated 10-year total cardiovascular disease risk . The 2025 guideline replaced the Pooled Cohort Equations with the American Heart Association PREVENT equations ( P redicting R isk of cardiovascular disease EVENT s), and lowered the drug-initiation trigger for stage 1 hypertension from a 10-year ASCVD risk of 10% to a 10-year PREVENT CVD risk of >=7.5% .

PREVENT versus the Pooled Cohort Equations (high-yield):

  • Feature Pooled Cohort Equations (2017) PREVENT (2025)
  • Outcome predicted ASCVD only (MI, stroke) Total CVD: ASCVD plus heart failure
  • Eligible ages 40-79 years 30-79 years
  • Time horizon 10-year 10-year and 30-year
  • Race as an input Race-based coefficients Race removed
  • Kidney / metabolic inputs None eGFR required ; optional UACR and HbA1c
  • Social risk None Optional social deprivation index

Stage 1 drug threshold 10-year ASCVD >=10% 10-year CVD >=7.5% +-----------------------------------------------------------------------------+

  • | ACC/AHA HYPERTENSION TREATMENT ALGORITHM |
  • | |
  • | [INITIAL BP ASSESSMENT] |
  • | | |
  • | +--------------------------+--------------------------+ |
  • | | | | |
  • | v v v |
  • | [ELEVATED BP] [STAGE 1 HTN] [STAGE 2 HTN] |
  • | (120-129/<80) (130-139/80-89) (>=140 or >=90) |
  • | | | | |
  • | v | v |
  • | [LIFESTYLE RX] | [LIFESTYLE RX +] |
  • | - Recheck in 3-6 mo | [INITIAL DUAL THERAPY]|
  • | | - 2 first-line agents |
  • | | - Recheck in 1 month |
  • | | |
  • | +----------------+----------------+ |
  • | | | |
  • | v v |
  • | [PREVENT 10-Yr CVD < 7.5% AND] [Clinical CVD OR DM OR CKD] |
  • | [No clinical CVD / DM / CKD] [OR PREVENT 10-Yr CVD >= 7.5%] |
  • | | | |
  • | v v |
  • | [LIFESTYLE RX FIRST] [LIFESTYLE RX +] |
  • | - 3 to 6 month trial [SINGLE FIRST-LINE AGENT] |
  • | - If BP still >= 130/80, - Recheck in 1 month |
  • | START drug therapy |
  • +-----------------------------------------------------------------------------+
  • Important
  • The single most testable 2025 change. Under the 2017 guideline, a stage 1 patient at low
  • risk was managed with lifestyle therapy indefinitely. Under the 2025 guideline that patient
  • is reassessed at 3 to 6 months and antihypertensive medication is started if blood pressure
  • remains >=130/80 mmHg . Low risk now delays drug therapy; it no longer exempts the patient
  • from it. +-----------------------------------------------------------------------------+
  • | 2025 GUIDELINE: OTHER HIGH-YIELD RECOMMENDATIONS |
  • | |
  • | POTASSIUM-BASED SALT SUBSTITUTE ...... Class 2a / Level A. Replaces sodium |
  • | chloride in home-cooked meals. |
  • | CAUTION in advanced CKD or with |
  • | K-sparing diuretics/ACEi/ARB/MRA. |
  • | ALCOHOL ............................. Ideally abstain; otherwise <= 2 |
  • | drinks/day (men), <= 1 (women). |
  • | HOME BP MONITORING .................. Class 1 to confirm the diagnosis and |
  • | to titrate therapy; validated |
  • | upper-arm cuff, correct cuff size. |
  • | PRIMARY ALDOSTERONISM SCREENING ..... ALL resistant hypertension, |
  • | regardless of serum potassium; |
  • | continue most antihypertensives |
  • | during screening. |
  • | COGNITION ........................... SBP < 130 mmHg is RECOMMENDED to |
  • | reduce cognitive decline/dementia. |
  • | PREGNANCY ........................... Treat chronic HTN to < 140/90 mmHg; |
  • | labetalol or ER nifedipine; aspirin |
  • | 81 mg from 12 weeks if at risk for |
  • | pre-eclampsia; NO ACEi/ARB/MRA or |
  • | nitroprusside. |
  • +-----------------------------------------------------------------------------+

Evidence-Based Non-Pharmacologic / Lifestyle Interventions:

Lifestyle Intervention Expected SBP Reduction (HTN) Clinical Details & Dietary Prescriptions

DASH Eating Plan -11 mmHg Diet rich in fruits, vegetables, whole grains, low-fat dairy; reduced saturated fat.

Weight Reduction -5 mmHg per 10 kg lost Maintain normal body mass index (BMI 18.5–24.9 kg/m 2 \text{kg/m}^2 kg/m 2 ). Rule of thumb: ~1 mmHg per 1 kg lost.

Dietary Sodium Reduction -5 to -6 mmHg Optimal goal: < 1 , 500 mg/day <1,500\text{ mg/day} < 1 , 500 mg/day ; realistic step target: reduction of ≥ 1 , 000 mg/day \ge 1,000\text{ mg/day} ≥ 1 , 000 mg/day .

Dietary Potassium Enhancement -4 to -5 mmHg Target: 3 , 500 – 5 , 000 mg/day 3,500–5,000\text{ mg/day} 3 , 500–5 , 000 mg/day via dietary sources (unless contraindicated by advanced CKD).

Structured Physical Activity -5 to -8 mmHg 90–150 min/week of moderate aerobic exercise (65–75% HR max) plus dynamic resistance.

Alcohol Moderation -4 mmHg Men: ≤ 2 \le 2 ≤ 2 standard drinks/day; Women: ≤ 1 \le 1 ≤ 1 standard drink/day.

4. First-Line Pharmacotherapy & Pharmacological Deep Dive

The 2025 ACC/AHA guideline retains the same four primary first-line drug classes for initiating hypertension treatment in non-Black patients without compelling co-morbidities: Thiazide Diuretics , Angiotensin-Converting Enzyme (ACE) Inhibitors , Angiotensin Receptor Blockers (ARBs) , and Dihydropyridine Calcium Channel Blockers (CCBs) . +-----------------------------------------------------------------------------+

  • | PRIMARY FIRST-LINE ANTIHYPERTENSIVE CLASSES |
  • | |
  • | [THIAZIDE-TYPE] ---> Chlorthalidone (preferred), Hydrochlorothiazide |
  • | [ACE INHIBITORS] ---> Lisinopril, Enalapril, Ramipril, Benazepril |
  • | [ARBs] ---> Losartan, Valsartan, Olmesartan, Candesartan |
  • | [DIHYDRO CCBs] ---> Amlodipine, Nifedipine ER, Felodipine |
  • +-----------------------------------------------------------------------------+
  • Comprehensive Antihypertensive Drug Comparison Table

Drug Class Prototype Agents & Dosing Primary Mechanism Adverse Effects & Monitoring Contraindications & Black Box Warnings

Thiazide Diuretics Chlorthalidone (12.5–25 mg daily); HCTZ (12.5–50 mg daily) Inhibits Na + / Cl − \text{Na}^+/\text{Cl}^- Na + / Cl − cotransporter in distal convoluted tubule; promotes natriuresis and long-term vasodilation. Hypokalemia, hyponatremia, hypomagnesemia, hyperuricemia (precipitates gout) , hypercalcemia , mild hyperglycemia. History of severe gout; anuria; sulfa allergy cross-reactivity (rare). Ineffective if eGFR < 30 mL/min \text{eGFR} < 30\text{ mL/min} eGFR < 30 mL/min (switch to loop diuretic).

ACE Inhibitors (ACEi) Lisinopril (10–40 mg daily); Enalapril (5–40 mg daily); Ramipril (2.5–20 mg daily) Blocks conversion of Angiotensin I to Angiotensin II; reduces aldosterone; blocks bradykinin degradation. Dry hacking cough (5–20% due to bradykinin) , angioedema , hyperkalemia, acute kidney injury (transient SCr \text{SCr} SCr rise up to 30% acceptable). Pregnancy (Black Box: Teratogenic/fetal renal dysgenesis) , bilateral renal artery stenosis, history of ACEi angioedema.

Angiotensin Receptor Blockers (ARBs) Losartan (25–100 mg daily); Valsartan (80–320 mg daily); Olmesartan (20–40 mg daily) Competitively blocks AT1 receptors; no effect on bradykinin metabolism. Hyperkalemia, azotemia, dizziness. Lower incidence of angioedema (<0.5%); no bradykinin cough. Pregnancy (Black Box: Teratogenic) , bilateral renal artery stenosis. Never combine ACEi + ARB (causes hyperkalemia and renal failure without benefit).

Dihydropyridine CCBs Amlodipine (2.5–10 mg daily); Nifedipine ER (30–90 mg daily) Potent arterial vasodilation via L-type voltage-gated calcium channels in vascular smooth muscle. Dose-dependent peripheral ankle edema (precapillary dilation), reflex tachycardia, flushing, headache, gingival hyperplasia. Severe aortic stenosis; cardiogenic shock. Note: Peripheral edema is not volume overload (unresponsive to diuretics; treat by adding ACEi/ARB).

Non-Dihydropyridine CCBs Diltiazem CD (120–360 mg daily); Verapamil SR (120–480 mg daily) Inhibits L-type calcium channels in myocardium and SA/AV nodes; negative inotrope and chronotrope. Bradycardia, 1st–3rd degree AV block, severe constipation (verapamil) , CYP3A4 inhibition (drug interactions with statins). Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤40%) , 2nd/3rd degree AV block, sick sinus syndrome.

Beta-Blockers (BB) Metoprolol Succinate (25–200 mg); Carvedilol (3.125–25 mg BID); Bisoprolol (2.5–10 mg) Antagonizes β 1 \beta_1 β 1 ​ (and α 1 \alpha_1 α 1 ​ for carvedilol) adrenergic receptors; reduces cardiac output and renin release. Bradycardia, bronchospasm, fatigue, exercise intolerance, masked hypoglycemia symptoms (sweating preserved), erectile dysfunction. Not first-line for primary HTN without compelling indication (post-MI, HFrEF, CAD, angina). Contraindicated in severe asthma/COPD with bronchospasm, decompensated HF, high-grade AV block.

Note

Chlorthalidone vs. Hydrochlorothiazide (HCTZ): The ACC/AHA guidelines (2017 and 2025 alike) prefer Chlorthalidone over HCTZ because of its longer terminal elimination half-life (40–60 hours vs. 6–12 hours) and robust cardiovascular event reduction demonstrated in milestone trials (ALLHAT, SHEP). When prescribing, note that chlorthalidone is roughly 1.5–2 times as potent as HCTZ milligram-for-milligram (12.5–25 mg chlorthalidone ≈ \approx ≈ 25–50 mg HCTZ).

5. Compelling Indications & Special Populations

Tailoring antihypertensive regimens to co-existing medical conditions represents one of the most heavily tested domains on the AGPCNP board exam. +-----------------------------------------------------------------------------+

  • | COMPELLING INDICATIONS FOR DRUG SELECTION |
  • | |
  • | CLINICAL PROFILE FIRST-LINE DRUG CHOICES |
  • | ----------------------------------------------------------------------- |
  • | Black Adult (without CKD) Thiazide (Chlorthalidone) OR DHP-CCB |
  • | CKD (Stage 3+ or Albuminuria >=30) ACEi OR ARB (Slows progression) |
  • | Diabetes Mellitus with Albuminuria ACEi OR ARB |
  • | Heart Failure with Reduced EF ARNI/ACEi + Beta-Blocker + MRA + SGLT2|
  • | Post-Myocardial Infarction / CAD Beta-Blocker + ACEi/ARB |
  • | Thoracic Aortic Aneurysm Beta-Blocker |
  • | Recurrent Nephrolithiasis (Calcium) Thiazide (reduces urinary calcium) |
  • | Osteoporosis Thiazide (spares renal calcium excretion)|
  • | Benign Prostatic Hyperplasia (BPH) Alpha-1 Blocker (Doxazosin - Adjunct) |
  • | Pregnancy / Pre-Conception Labetalol, Nifedipine ER, Methyldopa |
  • +-----------------------------------------------------------------------------+

Clinical Nuances by Population:

Black Adults (ALLHAT Evidence): In Black patients with hypertension but without CKD or heart failure, initial therapy should comprise a Thiazide diuretic or Dihydropyridine CCB . Monotherapy with ACE inhibitors or ARBs yields lower blood pressure reduction and significantly higher rates of stroke and angioedema (2–4x higher risk) due to lower baseline plasma renin levels. However, if a Black patient has CKD with proteinuria (albumin/creatinine ratio ≥ 300 mg/g \ge 300\text{ mg/g} ≥ 300 mg/g ), an ACEi or ARB is mandated as first-line to protect glomerular function.

Chronic Kidney Disease (CKD): In patients with CKD Stage 3 or higher, or Stage 1–2 with albuminuria (urine albumin ≥ 300 mg/day \ge 300\text{ mg/day} ≥ 300 mg/day or urine albumin/creatinine ratio ≥ 30 mg/g \ge 30\text{ mg/g} ≥ 30 mg/g ), initiate an ACEi or ARB . Monitor serum potassium and creatinine within 1–2 weeks. A transient serum creatinine increase up to 30% above baseline is expected and acceptable due to efferent arteriolar vasodilation reducing intraglomerular hyperfiltration pressure. Do not discontinue the drug unless the creatinine rise exceeds 30% or refractory hyperkalemia occurs.

Geriatric Patients (Age ≥65): The SPRINT trial demonstrated that targeting SBP < 130 mmHg <130\text{ mmHg} < 130 mmHg in non-institutionalized, ambulatory community-dwelling older adults significantly reduces cardiovascular events and all-cause mortality without increasing injurious falls. However, avoid over-aggressive titration in frail elders or those with severe orthostatic hypotension. Check sitting and standing blood pressures at every visit.

6. Resistant Hypertension: Definition, Pseudo-Resistance & MRA Therapy

Resistant Hypertension is defined as blood pressure that remains uncontrolled ( ≥ 130 / 80 mmHg \ge 130/80\text{ mmHg} ≥ 130/80 mmHg ) despite concurrent adherence to three antihypertensive agents of different classes at maximally tolerated doses , one of which must be a diuretic ; or blood pressure that requires four or more antihypertensive medications to achieve control. +-----------------------------------------------------------------------------+

  • | RESISTANT HYPERTENSION EVALUATION FLOWCHART |
  • | |
  • | [BP >= 130/80 ON 3 DRUGS (INCLUDING MAX-DOSE DIURETIC)] |
  • | | |
  • | v |
  • | [STEP 1: EXCLUDE PSEUDO-RESISTANCE] |
  • | - Medication non-adherence (assess via pharmacy fill history) |
  • | - White-coat effect (confirm via 24-hr ABPM or HBPM) |
  • | - Inaccurate cuff sizing or poor measurement technique |
  • | - Interfering substances (NSAIDs, decongestants, systemic steroids, |
  • | stimulants, licorice, excessive alcohol) |
  • | | |
  • | v |
  • | [STEP 2: SCREEN FOR SECONDARY HYPERTENSION] |
  • | - Obstructive Sleep Apnea (OSA) -> STOP-BANG screening |
  • | - Primary Aldosteronism -> Aldosterone-to-Renin Ratio (ARR) |
  • | - Renal Artery Stenosis -> Renal duplex Doppler US |
  • | - CKD -> eGFR, urinalysis, urine albumin/creatinine ratio |
  • | | |
  • | v |
  • | [STEP 3: OPTIMIZE PHARMACOTHERAPY (PATHWAY-2 PROTOCOL)] |
  • | - Ensure optimal 3-drug backbone: ACEi/ARB + DHP-CCB + Chlorthalidone |
  • | - ADD 4th-Line Agent: SPIRONOLACTONE (25-50 mg daily) or EPLERENONE |
  • | - Monitor K+ and eGFR (contraindicated if K+ > 5.0 mEq/L or eGFR < 30) |
  • +-----------------------------------------------------------------------------+

The PATHWAY-2 Trial & Spironolactone:

The milestone PATHWAY-2 trial demonstrated that occult aldosterone excess and persistent sodium retention drive resistant hypertension. The addition of the mineralocorticoid receptor antagonist Spironolactone (25–50 mg daily) is significantly more effective at lowering blood pressure in resistant HTN than adding a beta-blocker (bisoprolol) or alpha-blocker (doxazosin). If spironolactone induces gynecomastia or breast tenderness (due to anti-androgenic effects), substitute Eplerenone (50–100 mg daily) , a selective mineralocorticoid antagonist.

7. Secondary Hypertension: Clinical Clues, Workups & Target Pathologies

Secondary hypertension accounts for 5–10% of adult hypertension cases and up to 20–30% in specialized referral centers. The AGPCNP must recognize clinical "red flags" triggering a secondary workup. +-----------------------------------------------------------------------------+

  • | CLINICAL RED FLAGS FOR SECONDARY HYPERTENSION |
  • | |
  • | * Abrupt or sudden onset of severe HTN in patients < 30 or > 55 years |
  • | * Previously well-controlled HTN with acute, refractory loss of control |
  • | * Resistant HTN (uncontrolled on 3 full-dose medications) |
  • | * Severe target organ damage disproportionate to duration of HTN |
  • | * Onset of Stage 2 HTN in a non-obese, young patient without family history|
  • | * Acute rise in serum creatinine > 30-35% after starting ACEi or ARB |
  • | * Unexplained spontaneous or diuretic-induced hypokalemia |
  • +-----------------------------------------------------------------------------+
  • Comprehensive Secondary Hypertension Diagnostic Matrix

Etiology Pathophysiology & Clinical Clues Initial Screening Test Confirmatory Diagnostic Modality

Obstructive Sleep Apnea (OSA) Intermittent hypoxia, sympathetic surge. Snoring, daytime somnolence, morning headaches, thick neck ( > 17 >17 > 17 in men, > 16 >16 > 16 in women). STOP-BANG Questionnaire Overnight Polysomnography (Diagnostic: Apnea-Hypopnea Index AHI ≥ 5 \text{AHI} \ge 5 AHI ≥ 5 ).

Renal Artery Stenosis (RAS) Atherosclerosis in elderly males; Fibromuscular Dysplasia (FMD) in young females ( < 30 <30 < 30 ). Epigastric/flank abdominal bruit, flash pulmonary edema, acute SCr \text{SCr} SCr rise > 30 % >30\% > 30% post-ACEi. Renal Artery Duplex Doppler Ultrasonography CT Angiography (CTA), MR Angiography (MRA), or Catheter Angiography (string-of-beads in FMD).

Primary Aldosteronism (Conn's) Adrenal adenoma or bilateral adrenal hyperplasia. Triad of HTN, hypokalemia (50% normokalemic!), metabolic alkalosis, muscle cramps. Morning Plasma Aldosterone Concentration (PAC) to Plasma Renin Activity (PRA) Ratio (ARR) . Screen positive if ARR > 20 – 30 \text{ARR} > 20–30 ARR > 20–30 with PAC ≥ 15 ng/dL \text{PAC} \ge 15\text{ ng/dL} PAC ≥ 15 ng/dL . Oral sodium loading or saline infusion suppression test; Adrenal CT scan + Adrenal Vein Sampling (AVS).

Pheochromocytoma Catecholamine-secreting chromaffin tumor. Paroxysmal triad ( The 3 Ps ): Pounding Headache , Profuse Perspiration , Palpitations/Tachycardia , with severe paroxysmal HTN. Plasma Free Metanephrines (high sensitivity) or 24-hour Urinary Fractionated Metanephrines and Catecholamines . Abdominal CT/MRI with IV contrast; 123 I-MIBG {}^{123}\text{I-MIBG} 123 I-MIBG scintigraphy. Pre-op: α \alpha α -blocker (phenoxybenzamine) before β \beta β -blocker!

Cushing's Syndrome Hypercortisolemia. Central obesity, moon facies, buffalo hump, purple abdominal striae ( > 1 cm >1\text{ cm} > 1 cm ), proximal muscle weakness, hyperglycemia. 24-Hour Urinary Free Cortisol , 1-mg Overnight Dexamethasone Suppression Test , or Late-Night Salivary Cortisol (2 abnormal tests required). Plasma ACTH level; pituitary MRI vs. Adrenal CT.

Coarctation of the Aorta Congenital luminal narrowing distal to left subclavian. Upper extremity HTN with diminished/delayed femoral pulses ( radial-femoral delay ), BP arms ≫ BP legs \text{BP}_{\text{arms}} \gg \text{BP}_{\text{legs}} BP arms ​ ≫ BP legs ​ . Bilateral upper/lower extremity BP and pulse volume recording; CXR showing "rib notching" (collateral intercostal flow) and "Figure 3 sign" . Transthoracic / Transesophageal Echocardiography or Cardiac MRA/CTA.

Renal Parenchymal Disease Glomerulonephritis, diabetic nephropathy, polycystic kidney disease (PKD). Elevated creatinine, proteinuria, hematuria, bilateral flank masses (PKD). Serum Creatinine / eGFR, Urinalysis, Spot Urine Albumin/Creatinine Ratio Renal Ultrasonography (small echogenic kidneys in CKD; bilateral enlarged cystic kidneys in ADPKD).

Warning

Pheochromocytoma Management Trap: Never administer a beta-blocker as monotherapy to a patient with suspected or confirmed pheochromocytoma without first achieving complete alpha-adrenergic blockade (e.g., with phenoxybenzamine or doxazosin). Blocking β 2 \beta_2 β 2 ​ -mediated skeletal vasodilation while leaving α 1 \alpha_1 α 1 ​ -mediated vasoconstriction unopposed leads to catastrophic, life-threatening paradoxical hypertensive crisis and acute myocardial infarction.

8. Severe Hypertension vs. Hypertensive Emergency

Markedly elevated blood pressure is defined as SBP > 180 mmHg >180\text{ mmHg} > 180 mmHg and/or DBP > 120 mmHg >120\text{ mmHg} > 120 mmHg . Management depends strictly on the presence or absence of acute, progressive target-organ damage .

Warning

Terminology change you must use. The 2025 ACC/AHA guideline retired the term "hypertensive urgency." Markedly elevated blood pressure without acute target-organ damage is now called severe hypertension . "Hypertensive emergency " is unchanged and still means severe elevation with acute target-organ damage. The clinical actions did not change - only the label - but newer items and distractors will use the 2025 wording. +-----------------------------------------------------------------------------+

  • | HYPERTENSIVE CRISIS DECISION MATRIX |
  • | |
  • | [SEVERE ELEVATION: BP > 180 / 120 mmHg] |
  • | | |
  • | +--------------------------+--------------------------+ |
  • | | | |
  • | v v |
  • | [NO TARGET ORGAN DAMAGE] [ACUTE TARGET ORGAN DAMAGE]|
  • | = SEVERE HYPERTENSION (2025 term, = HYPERTENSIVE EMERGENCY|
  • | formerly "hypertensive urgency") |
  • | - Severe headache, epistaxis, anxiety - Encephalopathy, Stroke|
  • | - Management: Outpatient oral meds - Acute Aortic Dissection|
  • | - Gradual reduction over 24-48 hrs - Acute Pulmonary Edema |
  • | - Oral Captopril, Clonidine, Labetalol - Acute Coronary Syndrome|
  • | - Follow-up within 24-48 hours - Acute Renal Failure |
  • | - Management: ICU, IV meds|
  • | - MAP Protocol: <=25% 1st hr|
  • +-----------------------------------------------------------------------------+

Clinical Comparison & Management Protocols:

Feature Severe Hypertension (formerly "urgency") Hypertensive Emergency

Definition SBP > 180 >180 > 180 and/or DBP > 120 mmHg >120\text{ mmHg} > 120 mmHg WITHOUT acute target-organ damage. SBP > 180 >180 > 180 and/or DBP > 120 mmHg >120\text{ mmHg} > 120 mmHg WITH acute target-organ damage.

Clinical Manifestations Asymptomatic, mild-to-moderate headache, lightheadedness, shortness of breath, anxiety, epistaxis. Hypertensive encephalopathy (altered mental status, seizures, papilledema), acute ischemic/hemorrhagic stroke, acute aortic dissection, acute MI, acute pulmonary edema with LV failure, acute renal failure, eclampsia.

Level of Care Outpatient primary care or urgent care. Immediate ICU admission with continuous arterial line BP monitoring.

Treatment Strategy Oral antihypertensive agents (e.g., oral Captopril, Labetalol, or Clonidine; or re-initiating/intensifying outpatient regimen). Intravenous continuous infusions (Nicardipine, Labetalol, Clevidipine, Sodium Nitroprusside, Nitroglycerin, Esmolol).

Rate of BP Reduction Slow and controlled over 24 to 48 hours . Rapid drops are dangerous and precipitate cerebral or myocardial hypoperfusion. Standard MAP Protocol: Reduce Mean Arterial Pressure (MAP) by no more than 20–25% within the 1st hour ; if stable, reduce toward 160 / 100 – 110 mmHg 160/100–110\text{ mmHg} 160/100–110 mmHg over next 2–6 hours; then gradual normalization over 24–48 hours.

Critical Exceptions to Standard MAP Reduction Rule:

Acute Aortic Dissection: Rapid, aggressive SBP reduction to < 120 mmHg <120\text{ mmHg} < 120 mmHg and heart rate < 60 bpm <60\text{ bpm} < 60 bpm within 20 minutes using IV beta-blockers (Esmolol or Labetalol) followed by vasodilators to reduce shear stress ( dP/dt \text{dP/dt} dP/dt ). Vasodilators must never be given before beta-blockade.

Acute Ischemic Stroke (Thrombolysis Candidates): Lower BP cautiously to < 185 / 110 mmHg <185/110\text{ mmHg} < 185/110 mmHg prior to administering IV alteplase/tenecteplase, and maintain < 180 / 105 mmHg <180/105\text{ mmHg} < 180/105 mmHg for 24 hours post-thrombolysis.

Acute Ischemic Stroke (Non-Thrombolysis): Permissive hypertension is maintained; do not treat blood pressure unless SBP > 220 mmHg >220\text{ mmHg} > 220 mmHg or DBP > 120 mmHg >120\text{ mmHg} > 120 mmHg , then lower MAP by only 15% over 24 hours.